---
title: "Wall Street Zen Downgrades Cellectis (NASDAQ:CLLS) to Sell"
description: "Wall Street Zen has downgraded Cellectis (NASDAQ:CLLS) from a \"hold\" to a \"sell\" rating. Barclays also reduced its price target for Cellectis from $5.00 to $4.00 while maintaining an \"overweight\" rati"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/241716959.md"
published_at: "2025-05-24T15:02:51.000Z"
---

# Wall Street Zen Downgrades Cellectis (NASDAQ:CLLS) to Sell

> Wall Street Zen has downgraded Cellectis (NASDAQ:CLLS) from a "hold" to a "sell" rating. Barclays also reduced its price target for Cellectis from $5.00 to $4.00 while maintaining an "overweight" rating. Cellectis shares traded up 0.3% to $1.53, with a market cap of $84.77 million. The company reported a quarterly EPS of ($0.18), missing estimates, and anticipates a fiscal year EPS of -0.46. Institutional investors hold 63.90% of the stock, indicating significant interest in the company.

Cellectis (NASDAQ:CLLS - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Thursday.

-   Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal

Separately, Barclays reduced their price target on Cellectis from $5.00 to $4.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 13th.

**Check Out Our Latest Stock Report on Cellectis**

## Cellectis Trading Up 0.3%

Shares of NASDAQ:CLLS traded up $0.01 on Thursday, reaching $1.53. 6,779 shares of the company traded hands, compared to its average volume of 141,894. Cellectis has a 52 week low of $1.10 and a 52 week high of $2.95. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48. The business's 50-day simple moving average is $1.40 and its 200 day simple moving average is $1.58. The stock has a market capitalization of $84.77 million, a P/E ratio of -1.17 and a beta of 3.11.

Cellectis (NASDAQ:CLLS - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.03). Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. The firm had revenue of $12.03 million during the quarter, compared to the consensus estimate of $12.71 million. As a group, equities analysts anticipate that Cellectis will post -0.46 EPS for the current fiscal year.

## Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. OLD Mission Capital LLC bought a new stake in Cellectis in the 1st quarter worth approximately $31,000. Wells Fargo & Company MN grew its holdings in shares of Cellectis by 103.4% in the fourth quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company's stock valued at $44,000 after purchasing an additional 12,500 shares in the last quarter. Acadian Asset Management LLC increased its position in Cellectis by 132.9% in the first quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company's stock worth $55,000 after purchasing an additional 26,461 shares during the last quarter. Millennium Management LLC purchased a new stake in Cellectis during the fourth quarter valued at $962,000. Finally, B Group Inc. purchased a new stake in Cellectis during the fourth quarter valued at $5,547,000. 63.90% of the stock is currently owned by institutional investors.

## About Cellectis

(Get Free Report)

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.

## Featured Articles

-   Five stocks we like better than Cellectis
-   How to Profit From Growth Investing
-   3 Buy-and-Hold Stocks Long-Term Investors Can Love in Any Market
-   EV Stocks and How to Profit from Them
-   These 4 Top Investors Bought Over 6 Million Broadcom Shares in Q1
-   How to Plot Fibonacci Price Inflection Levels
-   Buy the Dip? 3 Oil Stocks Poised for a Big Comeback

*This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.*

## Should You Invest $1,000 in Cellectis Right Now?

Before you consider Cellectis, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellectis wasn't on the list.

While Cellectis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

### Related Stocks

- [CLLS.US - Cellectis](https://longbridge.com/en/quote/CLLS.US.md)
- [BCS.US - Barclays](https://longbridge.com/en/quote/BCS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| ConocoPhillips considers selling Permian assets worth $2 billion, Bloomberg News reports | Feb 20 (Reuters) - ConocoPhillipsis exploring a sale of some of its Permian Basin assets as part of a broader streamlini | [Link](https://longbridge.com/en/news/276478732.md) |
| IronBridge Private Wealth LLC Has $905,000 Holdings in Apple Inc. $AAPL | IronBridge Private Wealth LLC reduced its stake in Apple Inc. (NASDAQ:AAPL) by 77.3% in Q3, holding 3,555 shares valued  | [Link](https://longbridge.com/en/news/276436345.md) |
| Financial Advocates Investment Management Lowers Stock Position in Meta Platforms, Inc. $META | Financial Advocates Investment Management reduced its stake in Meta Platforms, Inc. by 66.7% in Q3, now holding 2,343 sh | [Link](https://longbridge.com/en/news/276432394.md) |
| Rocket Lab Corporation $RKLB Stock Holdings Increased by Vanguard Group Inc. | Vanguard Group Inc. increased its stake in Rocket Lab Corporation (NASDAQ:RKLB) by 5.4% in Q3, owning 41.8 million share | [Link](https://longbridge.com/en/news/276451972.md) |
| Alphabet Inc. $GOOG Shares Sold by Fifth Third Bancorp | Fifth Third Bancorp reduced its stake in Alphabet Inc. (NASDAQ:GOOG) by 0.4% in Q3, now holding 1,185,382 shares valued  | [Link](https://longbridge.com/en/news/276432399.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
